Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Genitourinary 1Endocrine 1Breast 1

Conditions

Somatostatinoma 1Mucositis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Islet Cell 1Breast Neoplasms 1

Interventions

Radiotherapy 9Cisplatin 8Fibroblast Growth Factor 7 6Low-Level Light Therapy 5angiotensin I (1-7) 4Radiation 4Injections 4Propolis 3Morphine 3Methotrexate 3Leucovorin 3Drug Therapy 3Cryotherapy 3glucarpidase 2aluminum hydroxide, magnesium hydroxide, drug combination 2Xylitol 2Water 2Radiotherapy, Intensity-Modulated 2RRx-001 2Probiotics 2Pentoxifylline 2Mouthwashes 2Melphalan 2Lidocaine 2Ketamine 2Interleukin 1 Receptor Antagonist Protein 2Honey 2Glutamine 2Gabapentin 2Fluorouracil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mucositis × Everolimus × Other × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡